Charles River Rapid Cell Banking Programs Cut Production Timelines by 40% With NGS Characterization
Charles River Laboratories (NYSE: CRL) has introduced rapid cell banking programs that the company says cut cell bank production timelines by 40% against a 20-week industry standard. The offering pairs rapid microbiological and mycoplasma tests with NGS characterization through its iDTECT platform.
